Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 7,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Terminated Not applicable Interventional

Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer

NCT00948285
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 30, 2026, 8:51 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

NCT04837209
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Niraparib, Dostarlimab, Radiation therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Effect of Radiation on Tissue for Delayed Breast Reconstruction

NCT01666899
View directory record Official record
Conditions
Breast Cancer
Interventions
Skin and blood vessel procedures
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Phase 1Phase 2 Interventional

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

NCT01100463
View directory record Official record
Conditions
Palmar-Plantar Erythrodysesthesia, Breast Cancer
Interventions
Cream, 0.1% Uracil Cream
Drug
Lead sponsor
Nanometics (d.b.a. PHD Biosciences)
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Phase 2 Interventional

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

NCT00049114
View directory record Official record
Conditions
Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, tipifarnib, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 30, 2026, 8:51 PM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

NCT03202316
View directory record Official record
Conditions
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Interventions
Atezolizumab, Cobimetinib, Eribulin, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Internet-based System for Cancer Patients to Self-report Toxicity

NCT00578006
View directory record Official record
Conditions
Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
Interventions
Questioners, STAR website
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Not applicable Interventional

LOL: It's All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer

NCT02892006
View directory record Official record
Conditions
Distress, Breast Neoplasms, Quality of Life
Interventions
Improvisational Comedy
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 30, 2026, 8:51 PM EDT
Recruiting Not applicable Interventional

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884
View directory record Official record
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Dublin, California • Fremont, California • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 8:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

NCT04927884
View directory record Official record
Conditions
Advanced Triple Negative Breast Cancer
Interventions
N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide
Biological · Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Weight Reduction Intervention for Breast Cancer Survivors

NCT00774371
View directory record Official record
Conditions
Breast Cancer
Interventions
Cognitive behavioral therapy CBT) for weight loss
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

NCT00455533
View directory record Official record
Conditions
Breast Cancer
Interventions
Ixabepilone, Paclitaxel, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Palm Springs, California • Coral Spring, Florida • Davie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 30, 2026, 8:51 PM EDT
Recruiting Not applicable Interventional

Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer

NCT06858449
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Whey protein (20 grams), Whey protein (60 grams)
Dietary Supplement
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
20 Years to 89 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Not applicable Interventional Results available

Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts

NCT05787249
View directory record Official record
Conditions
Breast Cancer
Interventions
Patient nudge, Provider nudge
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
1,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 8:51 PM EDT
Withdrawn Not applicable Interventional

A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads

NCT05365243
View directory record Official record
Conditions
Alopecia, Chemotherapy-induced Alopecia, Hair Loss, Breast Cancer, Gynecologic Cancer
Interventions
AMMA Portalbe Scalp Cooling System
Device
Lead sponsor
Cooler Heads Care Inc.
Government
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

NCT00153907
View directory record Official record
Conditions
Breast Cancer
Interventions
Navelbine, Capecitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 30, 2026, 8:51 PM EDT
Active, not recruiting Phase 2 Interventional

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

NCT04445844
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
Interventions
Pelareorep, Quality-of-Life Assessment, Questionnaire Administration, Retifanlimab
Biological · Other
Lead sponsor
Mridula George, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 30, 2026, 8:51 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309
View directory record Official record
Conditions
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 8:51 PM EDT
Active, not recruiting Phase 2 Interventional

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

NCT01334021
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Biopsy, Conventional Surgery, Genetic Testing
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Phase 4 Interventional

Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks

NCT01231204
View directory record Official record
Conditions
Paravertebral Catheter Insertion, Mastectomy, Breast Cancer
Interventions
Placebo (normal saline) Continuous Infusion, Ropivicaine 0.4% Continuous Infusion
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 30, 2026, 8:51 PM EDT
Completed Phase 2 Interventional

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

NCT01038804
View directory record Official record
Conditions
Breast Cancer
Interventions
YM155, Docetaxel
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Pleasant Hill, California • Lakeland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 30, 2026, 8:51 PM EDT
Completed No phase listed Observational

Peptide Profiles of Women Undergoing Breast Biopsy

NCT00587821
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 30, 2026, 8:51 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer

NCT01292733
View directory record Official record
Conditions
Ovarian Diseases, Ovarian Neoplasms
Interventions
Laboratory Tumor Marker Analysis, Transvaginal Ultrasound, Health Status Questionnaire
Other
Lead sponsor
Swedish Medical Center
Other
Eligibility
30 Years and older · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 30, 2026, 8:51 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

NCT01616758
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
GTx-024 9mg
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Miami, Florida • Peoria, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 30, 2026, 8:51 PM EDT